Xiaoping Su, Ph.D.
Department of Bioinformatics and Computational Biology, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Professor, Department of Bioinformatics and Computational Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Bioinformatics & Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2000 | Mount Sinai School of Medicine of New York University, New York, New York, US, Computational Biology, Ph.D |
| 1992 | Capital Institute of Medicine, Beijing, CN, Biostatistics, M.S |
| 1989 | Chongqing University, Chongqing, CN, Computer Sciences, BS |
Experience & Service
Faculty Academic Appointments
Associate Professor, Department of Bioinformatics & Comp Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2011 - 2017
Other Professional Positions
Bioinformatics Research Scientist/Manager, St. Jude Children's Research Hospital (SJCRH), Memphis, TN, 2003 - 2011
Senior Bioinformatics Scientist, Applied Biosystems, San Mateo, CA, 2001 - 2003
Bioinformatics Scientist, TissueInformatics, Inc, Pittsburgh, PA, 2000 - 2001
Senior Bioinformatics Analyst, OSI Pharmaceuticals, Melville, NY, 1999 - 2000
Extramural Institutional Committee Activities
member, Research Storage Planning & Governance Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
member, HPC governance, The University of Texas MD Anderson Cancer Center, 2015 - Present
member, Illumina Core Governance Committee member, The University of Texas MD Anderson Cancer Center, 2012 - Present
Professional Memberships
Selected Presentations & Talks
Formal Peers
- 2012. An algorithm to identify microbiome of human cancer tissue by deep-sequencing. Invited. Beijing, Beijing, CN.
- 2010. Detection of novel fusions by paired-end RNA-seq in leukemia. Invited. Thousand oaks, CA, US.
- 2010. Detection of novel fusions by paired-end transcriptome sequencing in leukemia. Invited. Nutley, NJ, US.
- 2010. Detection of novel fusions by paired-end transcriptome sequencing in AML. Invited. Boston, MA, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Targeting CDK7 in advanced MPN and AML transformed from MPN |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | FP00029264 |
| Date: | 2026 - 2028 |
| Title: | Novel synthetic compound UAS03 restores KRAB–ZFP–mediated repression of long terminal repeat (LTRs) to overcome colon cancer chemoresistance |
| Funding Source: | NIH via University of Louisville |
| Role: | PI |
| ID: | FP29466 |
| Date: | 2026 - 2031 |
| Title: | Developing rationally targeted novel drug combinations against mutant ASXL1 AML |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | FP00029272 |
| Date: | 2026 - 2031 |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer |
| Funding Source: | NCI |
| Role: | Co-leader |
| Date: | 2026 - 2031 |
| Title: | Novel Menin inhibitor-based combination therapy to improve efficacy and overcome resistance to Menin inhibitor |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | GRANT14424513 |
| Date: | 2026 - 2031 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2026 - 2031 |
| Title: | Developing rationally targeted combinations against MECOM-rearranged AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA311246 |
| Date: | 2025 - 2030 |
| Title: | Core B: Biostatistics and Bioinformatics Core |
| Funding Source: | NCI |
| Role: | Co-Leader |
| ID: | P50CA302482 |
| Date: | 2025 - 2030 |
| Title: | Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) |
| Funding Source: | NIDKK |
| Role: | Co-I |
| ID: | U01DK108328 |
| Date: | 2025 - 2030 |
| Title: | Role of targeting ATPases BRG1/BRM in therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA291918 |
| Date: | 2025 - 2030 |
| Title: | Improving efficacy and overcoming resistance to Menin inhibitor-based therapy in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA299192 |
| Date: | 2025 - 2029 |
| Title: | Studies to Characterize and overcome Menin inhibitor resistance in pediatric AML with MLL rearrangement |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250388 |
| Date: | 2024 - 2029 |
| Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA285472-01A1 |
| Date: | 2024 - 2029 |
| Title: | Defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA269651 |
| Date: | 2024 - 2029 |
| Title: | Role of targeting ATPases BRG1/BRM in therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA291918-01 |
| Date: | 2024 - 2029 |
| Title: | Histone chaperones and cell state regulation |
| Funding Source: | NIH/NIDDK |
| Role: | Principal Investigator-MDACC |
| ID: | R01DK133632 |
| Date: | 2024 - 2029 |
| Title: | Development of Rational and Effective Strategies to Treat Patients with Myeloproliferative Neoplasm-Blast Phase |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA289741-01 |
| Date: | 2024 - 2029 |
| Title: | Ex vivo expanded, cord derived human iNK T cells to improve the outcome of hematopoietic stem cell transplantation |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1 R01 CA282038-01A1 |
| Date: | 2023 - 2024 |
| Title: | Histone chaperones and cell state regulation |
| Funding Source: | University of Cincinnati |
| Role: | MPI |
| ID: | 1 R56 DK136632-01 |
| Date: | 2023 - 2028 |
| Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA285472-01 |
| Date: | 2023 - 2028 |
| Title: | Improving efficacy of Menin Inhibitor-based therapy of AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00018561 |
| Date: | 2023 - 2028 |
| Title: | SPORE University of Texas M.D. Anderson Cancer Center-Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | 2 P50 CA100632-21 |
| Date: | 2023 - 2028 |
| Title: | Developing novel Menin Inhibitor-based combinations for therapy of AML with MLL1 rearrangement or mutant NPM1 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA276036-01A1 |
| Date: | 2023 - 2030 |
| Title: | Elucidating and targeting epigenetic mechanisms and dysregulated transcriptome-based vulnerabilities to eradicate minimal residual disease Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R35 CA284027-01 |
| Date: | 2023 - 2028 |
| Title: | Ex vivo expanded, cord derived human iNK T cells to improve the outcome of hematopoietic stem cell transplantation |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA282038-01 |
| Date: | 2023 - 2028 |
| Title: | Biology and efficacy of Menin Inhibitors in AML therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA 272870 - 01 |
| Date: | 2022 - 2027 |
| Title: | Mechanistic target of rapamycin complex 1 (mTORC1) in repair-by-muscle after myocardial infarction |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP15853 |
| Date: | 2022 - 2027 |
| Title: | Role of CPSF6-RARG in Hematopoiesis and Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA 276272 - 01 |
| Date: | 2022 - 2027 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA047296 |
| Date: | 2022 - 2025 |
| Title: | Targeting metastatic niches in pancreatic cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | not available for this submission |
| Date: | 2022 - 2026 |
| Title: | Novel targeted therapy of AML |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | not available for this submission |
| Date: | 2021 - 2024 |
| Title: | Outcome of renal cell carcinoma: an integrative study of genomics, epigenomics, and intermediate biomarkers |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| ID: | W81XWH-20-KCRP-IDA |
| Date: | 2021 - 2025 |
| Title: | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) |
| Funding Source: | NIH/NIDDK |
| Role: | Co-I |
| ID: | U01DK108328 |
| Date: | 2021 - 2025 |
| Title: | Novel combination therapy for AML expressing mutant RUNX1 |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA262636 |
| Date: | 2021 - 2022 |
| Title: | CLL Moon Shot Priority Project #3: Targeting Pathophysiology of CLL |
| Funding Source: | MDACC Moonshot |
| Role: | Co-I |
| ID: | 710499-80-123129-21 |
| Date: | 2021 - 2026 |
| Title: | Disabling genetic drivers in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | TBD |
| Date: | 2021 - 2022 |
| Title: | Modeling pancreatic neuroendocrine tumorigenesis using human pluripotent stem cell differentiation |
| Funding Source: | Department of Defense (DOD) |
| Role: | Bioinformatician |
| ID: | W81XWH-20-RCRP-CA |
| Date: | 2021 - 2025 |
| Title: | Novel targeted therapies of AML stem-progenitor cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | GRANT#13281297 |
| Date: | 2021 - 2026 |
| Title: | Integrated Analyses of Mutant p53 as a Regulator of Lung Cancer Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Data Manager |
| ID: | RFA-CA-20-029 |
| Date: | 2021 - 2026 |
| Title: | Biology and novel therapy of Richter Transformation Diffuse Large B Cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA261729 |
| Date: | 2021 - 2026 |
| Title: | TBD |
| Funding Source: | NIH/NCI |
| Role: | Data Manager |
| ID: | RFA-CA-20-029 |
| Date: | 2021 - 2026 |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | 1 P50 CA247709-01A1 |
| Date: | 2021 - 2023 |
| Title: | Investigating Antigen Specificity of Tumor-Infiltrating B Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2020 - 2022 |
| Title: | Assessing BCL-XL inhibitors in models of Acute Myeloid Leukemia (AML) |
| Funding Source: | AbbVie |
| Role: | Co-I |
| ID: | AWD00005434 |
| Date: | 2020 - 2025 |
| Title: | Biology and novel therapy of AML expressing somatic or germline mutant RUNX1 |
| Funding Source: | NIH/NHLBI |
| Role: | Co-I |
| ID: | R01CA255721 |
| Date: | 2020 - 2022 |
| Title: | TGF-β Signaling and Immune-Targeted Therapies in Liver Tumors |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| Date: | 2020 - 2025 |
| Title: | Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA233457 |
| Date: | 2019 - 2024 |
| Title: | UPR/MDACC: Partnership for Excellence in Cancer Research |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 U54 CA096300-05 |
| Date: | 2019 - 2025 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | R01CA082577 |
| Date: | 2019 - 2026 |
| Title: | CCSG (CORE-001) Sequence and Microarray Facility |
| Funding Source: | NIH/NCI |
| Role: | Bioinformatician |
| ID: | P30CA016672 |
| Date: | 2019 - 2022 |
| Title: | Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R33 NS 111058 - 03 |
| Date: | 2019 - 2021 |
| Title: | Understanding the Physiologically Relevant Functions of Daxx |
| Funding Source: | Neuroendocrine Tumor Research Foundation |
| Role: | Collaborator |
| ID: | FP00006378 |
| Date: | 2018 - 2021 |
| Title: | Pembrolizumab Plus Radiation in Recurrent Osteosarcoma |
| Funding Source: | Emory University (Subaward via St. Baldrick's Foundation) |
| Role: | Principal Investigator-MDACC |
| Date: | 2018 - 2023 |
| Title: | UTMDACC Core 3 SPORE - Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 P50 CA100632-05 |
| Date: | 2018 - 2023 |
| Title: | Targeting dysregulated transcriptome as therapy for post-myeloproliferative neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA233457-01 |
| Date: | 2018 - 2021 |
| Title: | Targeting T-Acute Lymphoblastic Leukemia Initiating Cell (LIC) and Its Microenvironment with BRD4 and BET Family Proteolysis Targeting Chimera (PROTAC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP180174 |
| Date: | 2017 - 2022 |
| Title: | Center for Clinical and Translational Science |
| Funding Source: | UT Health Science Center Subaward (via NIH) |
| Role: | Collaborator |
| Date: | 2017 - 2026 |
| Title: | SIV- Takeda Global Research and Development Strategic Collaboration Agreement |
| Funding Source: | Takeda Global Research and Development |
| Role: | Co-I |
| ID: | RCTS60473 |
| Date: | 2017 - 2022 |
| Title: | Therapeutic targeting of dysregulated epigenome in Post Myeloproliferative Neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA 210250 - 05 |
| Date: | 2017 - 2022 |
| Title: | Deregulated PRAJA1-TGF-beta Signaling in Liver Cancer Stem Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2017 - 2022 |
| Title: | BRD4-antagonist-based combination therapy of Post-Myeloproliferative Neoplasm (MPN) sAML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA216905 |
| Date: | 2017 - 2017 |
| Title: | Genomic Alterations of Renal Pelvis, Ureter, and Bladder Carcinomas |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | Co-I |
| Date: | 2016 - 2022 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 2 R01 CA 047296 - 01 |
| Date: | 2016 - 2019 |
| Title: | Development of the first automated and universal CTC capture system toward precision medicine in pediatric/adolescent cancer patients |
| Funding Source: | The V Foundation for Cancer Research |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Batch effects in molecular profiling data on cancers: detection, quantitation, interpretation, and correction |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U24CA210949 |
| Date: | 2016 - 2021 |
| Title: | Role of Dlk1 Up-regulation in Wilms Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | BET protein antagonist-based targeted therapy of Mantle Cell Lymphoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2021 |
| Title: | Targeting ALL in the Hypoxic Microenvironment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 00017361 |
| Date: | 2016 - 2021 |
| Title: | MD Anderson Gynecologic SPORE for Uterine Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA98258 |
| Date: | 2016 - 2021 |
| Title: | Therapeutic targeting of glutamine metabolism in MDS |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA206210 |
| Date: | 2016 |
| Title: | Foundation AVEC Tools Bioinformatics |
| Funding Source: | Avec Foundation |
| Role: | PI |
| ID: | 600815-80-116120-19 |
| Date: | 2015 - 2019 |
| Title: | UPRCCC/MDACC: Partnership for Excellence in Cancer Research |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U54CA096300-13 |
| Date: | 2015 - 2018 |
| Title: | Systemic Functional Characterization of PPARG Gene Fusions in Bladder Cancer |
| Funding Source: | UTMDACC GU Bladder SPORE Development Award |
| Role: | PI |
| Date: | 2015 - 2020 |
| Title: | Therapeutic targeting of glutamine metabolism in MDS |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2015 - 2018 |
| Title: | Strategies to target the pathophysiology of CLL |
| Funding Source: | CLL Global Research Foundation |
| Role: | Co-I |
| Date: | 2015 - 2020 |
| Title: | Functional Integration of molecular phenotypes in childhood Wilms Tumors/Core 3 |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | UT Southwestern |
| Date: | 2015 - 2019 |
| Title: | (PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous Cell Epithelia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA194617 |
| Date: | 2014 - 2017 |
| Title: | A tool for assessing the risk of skin cancer through non-invasive epidermal sampling of UV-damaged DNA |
| Funding Source: | University of California- Santa Barbara |
| Role: | Co-I |
| ID: | 14068577 |
| Date: | 2014 - 2017 |
| Title: | Defining the Biological and Clinical Properties of the p53-like/Luminal A Subtype for Bladder Cancer |
| Funding Source: | the V Foundation for Cancer Research |
| Role: | Co-I |
| ID: | 123100-00002625-54 |
| Date: | 2014 - 2018 |
| Title: | Functional Genomic Analysis for Chemoprevention of Skin Cancer |
| Funding Source: | American Cancer Society- National |
| Role: | Co-I |
| Date: | 2014 - 2016 |
| Title: | Sensitivity/Specificity of the First Universal Sarcoma CTC Detection Tool |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1R21CA187944-01 |
| Date: | 2014 - 2019 |
| Title: | Effects of BRAF Inhibitors and Roles of Apoptosis in Human Skin Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 |
| Date: | 2014 - 2018 |
| Title: | Effects of BRAF Inhibitors:Roles of Apoptosis in Human Skin Cancer |
| Funding Source: | American Cancer Society- National |
| Role: | Co-I |
| Date: | 2014 - 2019 |
| Title: | Targeting Carcinoembryonic Antigen in Colon Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2R01CA042857-23A1 |
| Date: | 2014 - 2018 |
| Title: | (PQC3) Molecular mechanisms driving malignant progression in a mouse tumor model |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA184472-01 |
| Date: | 2014 - 2019 |
| Title: | Investigating the mechanistic roles of p63 in obesity and cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA183896-01 |
| Date: | 2014 - 2019 |
| Title: | Genomic Determinants of Cutaneous Squamous Cell Carcinoma Progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA183938-01 |
| Date: | 2013 - 2018 |
| Title: | Role of new liver progenitor cell population in hepatocellular carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA176564-01A1 |
| Date: | 2013 - 2017 |
| Title: | Center for Clinical and Translational Sciences (CCTS) |
| Funding Source: | NIH/NCI Subcontract from the University of Texas Health Science Center- Houston |
| Role: | Co-I |
| ID: | 4-UL1TR000371 |
| Date: | 2013 - 2018 |
| Title: | University of Texas M.D. Anderson Cancer Center SPORE - Leukemia (PC-C) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2P50CA100632 |
| Date: | 2013 - 2019 |
| Title: | Cancer Center Support (Core) Grant - Sequencing and Microarray Facilities (SMF) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 P30 CA016672 |
| Date: | 2013 - 2017 |
| Title: | (PQA2) Investigating the mechanistic roles of p63 in obesity and cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA179931-01 |
| Date: | 2013 - 2018 |
| Title: | Modeling Personalized Breast Cancer Therapy with Patient-derived Xenografts |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA178902-01 |
| Date: | 2013 - 2017 |
| Title: | Genetic Modeling and Targeted Therapy of PTEN and INK4A/ARF NULL T-ALL |
| Funding Source: | American Cancer Society- National |
| Role: | Co-I |
| Date: | 2013 - 2014 |
| Title: | Genomic Drivers of Cutaneous Squamous Cell Carcinoma |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | Co-I |
| Date: | 2013 - 2017 |
| Title: | (PQC3) Genomic Determinants of Cutaneous Squamous Cell Carcinoma Progression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01CA179983-01 |
| Date: | 2013 - 2017 |
| Title: | Implementing Genomically-Informed Personalized Therapy as Standard of Care |
| Funding Source: | National Human Genome Research Institute |
| Role: | Co-I |
| ID: | 1 U01 HG007286-01 |
| Date: | 2012 - 2015 |
| Title: | Sapacitabine therapy to create synthetic lethality in DNA repair-deficient CLL |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA163802-01A1 |
| Date: | 2012 - 2016 |
| Title: | Decision-Support for Personalized Medicine incorporating Genomic Data |
| Funding Source: | NIH/NLM |
| Role: | Co-I |
| ID: | 1 R01LM011341-01 |
| Date: | 2011 - 2016 |
| Title: | The Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (Core Projects: Colon Cancer, Skin Cancer) |
| Funding Source: | Michael and Susan Dell Foundation |
| Role: | Co-I |
| Date: | 2010 - 2012 |
| Title: | Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC) Supplement |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 3 U24 CA143883 02S2 |
| Date: | 2003 - 2021 |
| Title: | MD Anderson Gynecologic SPORE for Uterine Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50CA098258 |
| Date: | 1988 - 2021 |
| Title: | A Pathway of Tumor Suppression |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5 R01 CA 047296 - 33 |
Selected Publications
Peer-Reviewed Articles
- Fiskus W, Masarova L, Mill CP, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase. Blood Adv 9(21):5598-5609, 2025. e-Pub 2025. PMID: 40829105.
- Zhu, J, Ruan, X, Mangione, MC, Parra, P, Chen, G, Su, X, Luo, X, Cao, DJ. The cGAS-STING pathway promotes acute ischemia-induced neutropoiesis and neutrophil priming in the bone marrow. Basic Research in Cardiology 120(4):677-705, 2025. e-Pub 2025. PMID: 40332608.
- Yamatani, K, Watanabe, T, Saito, K, Khasawneh, A, Maiti, A, Zeng, Z, Hayes, K, Kimura, S, DiNardo, C, Su, X, Nojiri, S, Okazaki, Y, Andreeff, M, Konopleva, M, Tabe, Y. PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML. Blood Neoplasia 2(3), 2025. e-Pub 2025. PMID: 40757392.
- DiNardo CD, Jen WY, Montalban-Bravo G, Wang X, Loghavi S, Lavu S, Short NJ, Chien K, Issa GC, Pemmaraju N, Yilmaz M, Andreeff M, Borthakur G, Kadia TM, Daver NG, Garcia-Manero G, Mill CP, Su X, Fiskus W, Bhalla KN. Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1. Blood Neoplasia 2(4):100145, 2025. e-Pub 2025. PMID: 40979071.
- Helleux, A, Davidson, G, Lallement, A, Hourani, FA, Haller, AR, Michel, I, Fadloun, A, Thibault-Carpentier, C, Su, X, Lindner, V, Tricard, T, Lang, H, Tannir, NM, Davidson, I, Malouf, GG. TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma. EMBO Molecular Medicine 17(5):1041-1070, 2025. e-Pub 2025. PMID: 40148585.
- Lu X, Vano YA, Su X, Verkarre V, Sun CM, Cheng W, Xu L, Yan F, Kotti S, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma. NPJ Precis Oncol 9(1):134, 2025. e-Pub 2025. PMID: 40341678.
- Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
- Fiskus, WC, Mill, CP, Bose, P, Masarova, L, Pemmaraju, N, Dunbar, A, Birdwell, C, Davis, JA, Das, K, Hou, H, Manshouri, T, Jain, A, Malovannaya, A, Philip, K, Alhamadani, N, Matthews, A, Lin, K, Flores, L, Loghavi, S, DiNardo, C, Su, X, Rampal, R, Bhalla, K. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2025. e-Pub 2025. PMID: 39561280.
- Lu, X, Vano, Y, Su, X, Verkarre, V, Sun, CM, Cheng, W, Xu, L, Yan, F, Kotti, S, Fridman, WH, Sautès-Fridman, C, Oudard, S, Malouf, GG. Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma. Journal for immunotherapy of cancer 13(1), 2025. e-Pub 2025. PMID: 39848689.
- DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, Verma A, Konopleva M. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer 5(10):1515-1533, 2024. e-Pub 2024. PMID: 39300320.
- McDaniel JM, Morrissey RL, Dibra D, Patel LR, Xiong S, Zhang Y, Chau GP, Su X, Qi Y, El-Naggar AK, Lozano G. p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator. Cancer Res Commun 4(8):1991-2007, 2024. e-Pub 2024. PMID: 38994678.
- Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores LB, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
- Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
- Dibra D, Xiong S, Moyer SM, El-Naggar AK, Qi Y, Su X, Kong EK, Korkut A, Lozano G. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv 10(7):eadk1835, 2024. e-Pub 2024. PMID: 38354236.
- Mill CP, Fiskus WC, DiNardo CD, Reville P, Davis JA, Birdwell CE, Das K, Hou H, Takahashi K, Flores L, Ruan X, Su X, Loghavi S, Khoury JD, Bhalla KN. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J 14(1):25, 2024. e-Pub 2024. PMID: 38316746.
- Dibra D, Gagea M, Qi Y, Chau GP, Su X, Lozano G. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis. Cancer Res Commun 3(12):2640-2652, 2023. e-Pub 2023. PMID: 38047594.
- Su X, Lu X, Bazai SK, Dainese L, Verschuur A, Dumont B, Mouawad R, Xu L, Cheng W, Yan F, Irtan S, Lindner V, Paillard C, Le Bouc Y, Coulomb A, Malouf GG. Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors. Nat Commun 14(1):7884, 2023. e-Pub 2023. PMID: 38036539.
- Lu X, Vano YA, Su X, Helleux A, Lindner V, Mouawad R, Spano JP, Rouprêt M, Compérat E, Verkarre V, Sun CM, Bennamoun M, Lang H, Barthelemy P, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. Cell Rep Med 4(11):101287, 2023. e-Pub 2023. PMID: 37967556.
- Lu X, Tawanaie Pour Sedehi N, Su X, Yan F, Alhalabi O, Tannir NM, Malouf GG. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. Oncologist 28(11):1009-1013, 2023. e-Pub 2023. PMID: 37315151.
- Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, Elaidi RT, Verkarre V, Sun CM, Chevreau C, Bennamoun M, Lang H, Tricard T, Fridman WH, Sautes-Fridman C, Su X, Plassard D, Keime C, Thibault-Carpentier C, Barthelemy P, Oudard SM, Davidson I, Malouf GG. Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma. Cancer Res 83(17):2952-2969, 2023. e-Pub 2023. PMID: 37335139.
- Sun C, Qi Y, Fowlkes N, Lazic N, Su X, Lozano G, Wasylishen AR. The histone chaperone function of Daxx is dispensable for embryonic development. Cell Death Dis 14(8):565, 2023. e-Pub 2023. PMID: 37633949.
- Dibra D, Moyer SM, El-Naggar AK, Qi Y, Su X, Lozano G. Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A 120(34):e2308807120, 2023. e-Pub 2023. PMID: 37579145.
- Chachad D, Patel LR, Recio CV, Pourebrahim R, Whitley EM, Wang W, Su X, Xu A, Lee DF, Lozano G. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants. Cancer Res 83(14):2297-2311, 2023. e-Pub 2023. PMID: 37205631.
- Wang H, Moniruzzaman R, Li L, Ji B, Liu Y, Zuo X, Abbasgholizadeh R, Zhao J, Liu G, Wang R, Tang H, Sun R, Su X, Tan TH, Maitra A, Wang H. Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia. J Clin Invest 133(12), 2023. e-Pub 2023. PMID: 37140994.
- Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348, 2023. e-Pub 2023. PMID: 36977823.
- Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun 14(1):3034, 2023. e-Pub 2023. PMID: 37236926.
- Gencel-Augusto J, Su X, Qi Y, Whitley EM, Pant V, Xiong S, Shah V, Lin J, Perez E, Fiorotto ML, Mahmud I, Jain AK, Lorenzi PL, Navin NE, Richie ER, Lozano G. Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. Cancer Discov 13(5):1230-1249, 2023. e-Pub 2023. PMID: 37067911.
- Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, DiNardo CD, Takahashi K, Loghavi S, Soth MJ, Heffernan T, McGeehan GM, Ruan X, Su X, Vakoc CR, Daver N, Bhalla KN. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J 13(1):53, 2023. e-Pub 2023. PMID: 37055414.
- Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas. Clin Cancer Res 29(7):1279-1291, 2023. e-Pub 2023. PMID: 36374555.
- Mistretta B, Rankothgedera S, Castillo M, Rao M, Holloway K, Bhardwaj A, El Noafal M, Albarracin C, El-Zein R, Rezaei H, Su X, Akbani R, Shao XM, Czerniecki BJ, Karchin R, Bedrosian I, Gunaratne PH. Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer. Front Immunol 14:1188831, 2023. e-Pub 2023. PMID: 37744342.
- Stitzlein LM, Gangadharan A, Walsh LM, Nam D, Espejo AB, Singh MM, Patel KH, Lu Y, Su X, Ezhilarasan R, Gumin J, Singh S, Sulman E, Lang FF, Chandra J. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles. Front Neurol 14:1112207, 2023. e-Pub 2023. PMID: 37082446.
- Xiaoping S, Lu X, Bazai SK, Dainese L, Verschuur A, Dumont B, Mouawad R, Xu L, Cheng W, Yan F, Irtan S, Lindner V, Paillard C, Bouc Y, Coulomb A, and Malouf GG. Delineating the interplay between oncogenic pathways and immunity in anaplastic Wilms tumors: Implications for prognosis and therapeutic vulnerability. Nature Communication, 2023. e-Pub 2023. PMID: 38036539.
- Malouf, GG, Lu, X, Mouawad, R, Spano, JP, Grange, P, Yan, F, Aractingi, S, Su, X, Dupin, N. Genetic landscape of indolent and aggressive Kaposi sarcomas. Journal of the European Academy of Dermatology and Venereology 36(12):2343-2351, 2022. e-Pub 2022. PMID: 35881110.
- Chakravarthy A, Reddin I, Henderson S, Dong C, Kirkwood N, Jeyakumar M, Rodriguez DR, Martinez NG, McDermott J, Su X, Egawa N, Fjeldbo CS, Skingen VE, Lyng H, Halle MK, Krakstad C, Soleiman A, Sprung S, Lechner M, Ellis PJI, Wass M, Michaelis M, Fiegl H, Salvesen H, Thomas GJ, Doorbar J, Chester K, Feber A, Fenton TR. Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nat Commun 13(1):5818, 2022. e-Pub 2022. PMID: 36207323.
- Xiong S, Chachad D, Zhang Y, Gencel-Augusto J, Sirito M, Pant V, Yang P, Sun C, Chau G, Qi Y, Su X, Whitley EM, El-Naggar AK, Lozano G. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo. Cancer Res 82(10):1926-1936, 2022. e-Pub 2022. PMID: 35320355.
- Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 2022. e-Pub 2022. PMID: 35484100.
- Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, Takahashi K, Short N, Daver N, Ohanian M, Borthakur G, Kornblau SM, Green MR, Qi Y, Su X, Khoury JD, Bhalla KN. Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2. Blood 139(6):907-921, 2022. e-Pub 2022. PMID: 34601571.
- Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
- Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam F. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res 81(21):5572-5581, 2021. e-Pub 2021. PMID: 34518211.
- Villodre ES, Hu X, Larson R, Finetti P, Gomez K, Balema W, Stecklein SR, Santiago-Sanchez G, Krishnamurthy S, Song J, Su X, Ueno NT, Tripathy D, Van Laere S, Bertucci F, Vivas-Mejía P, Woodward WA, Debeb BG. Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Mol Oncol 15(10):2752-2765, 2021. e-Pub 2021. PMID: 34342930.
- Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol 206(3):548-557, 2021. e-Pub 2021. PMID: 33881933.
- Debien V, Davidson G, Baltzinger P, Kurtz JE, Séverac F, Imperiale A, Pessaux P, Addeo P, Bachellier P, Su X, Davidson I, Chenard MP, Goichot B, Malouf GG. Involvement of Neutrophils in Metastatic Evolution of Pancreatic Neuroendocrine Tumors. Cancers (Basel) 13(11), 2021. e-Pub 2021. PMID: 34199561.
- Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
- Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
- Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ. Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. Eur Urol Oncol 4(1):117-120, 2021. e-Pub 2021. PMID: 31411999.
- Su X, Lu X, Bazai SK, Compérat E, Mouawad R, Yao H, Rouprêt M, Spano JP, Khayat D, Davidson I, Tannir NN, Yan F, Malouf GG. Comprehensive integrative profiling of upper tract urothelial carcinomas. Genome Biol 22(1):7, 2021. e-Pub 2021. PMID: 33397444.
- Moyer SM, Wasylishen AR, Qi Y, Fowlkes N, Su X, Lozano G. p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proc Natl Acad Sci U S A 117(38):23663-23673, 2020. e-Pub 2020. PMID: 32900967.
- Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S, Group MC, working group PNSMCM, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L, Consortium P. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nat Commun 11(1):4748, 2020. e-Pub 2020. PMID: 32958763.
- Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N, Subtypes PT, Translation C, Boutros PC, Consortium P. Sex differences in oncogenic mutational processes. Nat Commun 11(1):4330, 2020. e-Pub 2020. PMID: 32859912.
- Wasylishen AR, Sun C, Moyer SM, Qi Y, Chau GP, Aryal NK, McAllister F, Kim MP, Barton MC, Estrella JS, Su X, Lozano G. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. Sci Adv 6(32):eaba8415, 2020. e-Pub 2020. PMID: 32821827.
- Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37(5):720-734.e13, 2020. e-Pub 2020. PMID: 32359397.
- Chen J, Mitra A, Li S, Song S, Nguyen BN, Chen JS, Shin JH, Gough NR, Lin P, Obias V, He AR, Yao Z, Malta TM, Noushmehr H, Latham PS, Su X, Rashid A, Mishra B, Wu RC, Mishra L. Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFβ Signaling. Cancer Res 80(9):1819-1832, 2020. e-Pub 2020. PMID: 32127355.
- Wasylishen AR, Sun C, Chau GP, Qi Y, Su X, Kim MP, Estrella JS, Lozano G. Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress. Proc Natl Acad Sci U S A 117(12):6622-6629, 2020. e-Pub 2020. PMID: 32156729.
- Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sültmann H, Moch H, Pathogens P, Cooper CS, Eils R, Ferretti V, Lichter P, Consortium P. The landscape of viral associations in human cancers. Nat Genet 52(3):320-330, 2020. e-Pub 2020. PMID: 32025001.
- Genomes Consortium IPAOW. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
- Malouf GG, Flippot R, Dong Y, Dinatale RG, Chen YB, Su X, Compérat E, Rouprêt M, Mano R, Blum KA, Yao H, Mouawad R, Spano JP, Khayat D, Karam JA, Ho TH, Tickoo SK, Russo P, Hsieh JJ, Tannir NM, Hakimi AA. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Sci Rep 10(1):701, 2020. e-Pub 2020. PMID: 31959902.
- Lu X, Jiang L, Zhang L, Zhu Y, Hu W, Wang J, Ruan X, Xu Z, Meng X, Gao J, Su X, Yan F. Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome. Neoplasia 21(6):591-601, 2019. e-Pub 2019. PMID: 31055200.
- Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220.e9, 2019. e-Pub 2019. PMID: 30753823.
- Zhao M, Zhuo ML, Zheng X, Su X, Meric-Bernstam F. FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells. Oncotarget 10(1):30-44, 2019. e-Pub 2019. PMID: 30713601.
- Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG. Immune Checkpoint Inhibitors in MITF Family Translocation Renal Cell Carcinomas and Genetic Correlates of Exceptional Responders. J Immunother Cancer 6(1):159, 2018. e-Pub 2018. PMID: 30591082.
- Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
- Classe M, Yao H, Mouawad R, Creighton CJ, Burgess A, Allanic F, Wassef M, Leroy X, Verillaud B, Mortuaire G, Bielle F, Le Tourneau C, Kurtz JE, Khayat D, Su X, Malouf GG. Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny. Cell Rep 25(3):811-821.e5, 2018. e-Pub 2018. PMID: 30332658.
- Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med 10(455), 2018. e-Pub 2018. PMID: 30135250.
- Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Atlas Network CG, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33(2):244-258.e10, 2018. e-Pub 2018. PMID: 29438696.
- Chen J, Zaidi S, Rao S, Chen JS, Phan L, Farci P, Su X, Shetty K, White J, Zamboni F, Wu X, Rashid A, Pattabiraman N, Mazumder R, Horvath A, Wu RC, Li S, Xiao C, Deng CX, Wheeler DA, Mishra B, Akbani R, Mishra L. Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor beta Pathway Short title: Prognostic significance of TGF-β signature in liver cancer. Gastroenterology 154(1):195-210, 2018. e-Pub 2018. PMID: 28918914.
- Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ, Network TR, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171(3):540-556.e25, 2017. e-Pub 2017. PMID: 28988769.
- Horstmann N, Sahasrabhojane P, Yao H, Su X, Shelburne SA. Use of a Phosphorylation Site Mutant To Identify Distinct Modes of Gene Repression by the Control of Virulence Regulator (CovR) in Streptococcus pyogenes. J Bacteriol 199(18), 2017. e-Pub 2017. PMID: 28289082.
- Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG. NSD1 inactivation and SETD2 mutation drive a convergence toward loss-of-function of H3K36 writers in clear-cell renal cell carcinomas. Cancer Res 77(18):4835-4845, 2017. e-Pub 2017. PMID: 28754676.
- Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep 7(1):8540, 2017. e-Pub 2017. PMID: 28819235.
- Research Network CGA. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169(7):1327-1341.e23, 2017. e-Pub 2017. PMID: 28622513.
- Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, Grégoire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Tannir NM, Leroy X. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology 70(7):1089-1097, 2017. e-Pub 2017. PMID: 28106924.
- Dai F, Lee H, Zhang Y, Zhuang L, Yao H, Xi Y, Xiao ZD, You MJ, Li W, Su X, Gan B. BAP1 inhibits the ER stress gene regulatory network and modulates metabolic stress response. Proc Natl Acad Sci U S A 114(12):3192-3197, 2017. e-Pub 2017. PMID: 28275095.
- Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong LN, Katz LH, Shetty K, Rashid A, Su X, White J, Li L, Wang AY, Blechacz B, Raju GS, Davila M, Nguyen BN, Stroehlein JR, Chen J, Kim SS, Levin H, Machida K, Tsukamoto H, Michaely P, Tzatsos A, Mishra B, Amdur R, Mishra L. Loss of the transforming growth factor-beta effector beta2-Spectrin promotes genomic instability. Hepatology 65(2):678-693, 2017. e-Pub 2017. PMID: 28114741.
- Johanning GL, Malouf GG, Zheng X, Esteva FJ, Weinstein JN, Wang-Johanning F, Su X. Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci Rep 7:41960, 2017. e-Pub 2017. PMID: 28165048.
- Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget 7(49):80164-80174, 2016. e-Pub 2016. PMID: 27845906.
- Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clin Cancer Res 22(24):6236-6246, 2016. e-Pub 2016. PMID: 27256309.
- Chakravarthy A, Henderson S, Thirdborough SM, Ottensmeier CH, Su X, Lechner M, Feber A, Thomas GJ, Fenton TR. Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. J Clin Oncol 34(34):4132-4141, 2016. e-Pub 2016. PMID: 27863190.
- Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S, Konopleva M. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget 7(48):79722-79735, 2016. e-Pub 2016. PMID: 27806325.
- Shen C, Meric-Bernstam F, Su X, Mendelsohn J, Giordano S. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget 7(44):71686-71695, 2016. e-Pub 2016. PMID: 27634896.
- Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J 6(9):e465, 2016. e-Pub 2016. PMID: 27588518.
- Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol 70(2):348-57, 2016. e-Pub 2016. PMID: 26895810.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J 6:e434, 2016. e-Pub 2016. PMID: 27284738.
- Chen J, Yao ZX, Chen JS, Gi YJ, Muñoz NM, Kundra S, Herlong HF, Jeong YS, Goltsov A, Ohshiro K, Mistry NA, Zhang J, Su X, Choufani S, Mitra A, Li S, Mishra B, White J, Rashid A, Wang AY, Javle M, Davila M, Michaely P, Weksberg R, Hofstetter WL, Finegold MJ, Shay JW, Machida K, Tsukamoto H, Mishra L. TGF-β/β2-spectrin/CTCF-regulated tumor suppression in human stem cell disorder Beckwith-Wiedemann syndrome. J Clin Invest 126(2):527-42, 2016. e-Pub 2016. PMID: 26784546.
- Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, Melott J, Weinstein J. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res 44(D1):D1018-22, 2016. e-Pub 2016. PMID: 26602693.
- Malouf GG, Compérat E, Yao H, Mouawad R, Lindner V, Rioux-Leclercq N, Verkarre V, Leroy X, Dainese L, Classe M, Descotes JL, Barthelemy P, Yacoub M, Rouprêt M, Bernhard JC, Creighton CJ, Spano JP, Su X, Khayat D. Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas. Sci Rep 6:30988, 2016. e-Pub 2016. PMID: 27484008.
- Chen J, Raju GS, Jogunoori W, Menon V, Majumdar A, Chen JS, Gi YJ, Jeong YS, Phan L, Belkin M, Gu S, Kundra S, Mistry NA, Zhang J, Su X, Li S, Lin SH, Javle M, McMurray JS, Rahlfs TF, Mishra B, White J, Rashid A, Beauchemin N, Weston BR, Shafi MA, Stroehlein JR, Davila M, Akbani R, Weinstein JN, Wu X, Mishra L. Mutational Profiles Reveal an Aberrant TGF-β-CEA Regulated Pathway in Colon Adenomas. PLoS One 11(4):e0153933, 2016. e-Pub 2016. PMID: 27100181.
- Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget 6(37):39865-76, 2015. e-Pub 2015. PMID: 26431491.
- Singh MM, Johnson B, Venkatarayan A, Flores ER, Zhang J, Su X, Barton M, Lang F, Chandra J. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol 17(11):1463-73, 2015. e-Pub 2015. PMID: 25795306.
- Dang J, Wei L, de Ridder J, Su X, Rust AG, Roberts KG, Payne-Turner D, Cheng J, Ma J, Qu C, Wu G, Song G, Huether RG, Schulman B, Janke L, Zhang J, Downing JR, van der Weyden L, Adams DJ, Mullighan CG. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. Blood 125(23):3609-17, 2015. e-Pub 2015. PMID: 25855603.
- Flores AR, Galloway-Peña J, Sahasrabhojane P, Saldaña M, Yao H, Su X, Ajami NJ, Holder ME, Petrosino JF, Thompson E, Margarit Y Ros I, Rosini R, Grandi G, Horstmann N, Teatero S, McGeer A, Fittipaldi N, Rappuoli R, Baker CJ, Shelburne SA. Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes. Proc Natl Acad Sci U S A 112(20):6431-6, 2015. e-Pub 2015. PMID: 25941374.
- Horstmann N, Sahasrabhojane P, Saldaña M, Ajami NJ, Flores AR, Sumby P, Liu CG, Yao H, Su X, Thompson E, Shelburne SA. Characterization of the Effect of the Histidine Kinase CovS on Response Regulator Phosphorylation in Group A Streptococcus. Infect Immun 83(3):1068-77, 2015. e-Pub 2015. PMID: 25561708.
- Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9(1):32-43, 2015. e-Pub 2015. PMID: 25126716.
- Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5(20):9864-9876, 2014. e-Pub 2014. PMID: 25296969.
- Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res 20(15):4129-40, 2014. e-Pub 2014. PMID: 24899691.
- Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol 11(7):400-10, 2014. e-Pub 2014. PMID: 24960601.
- Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-Mediated Cytosine Deamination Links PIK3CA Helical Domain Mutations to Human Papillomavirus-Driven Tumor Development. Cell Rep 7(6):1833-41, 2014. e-Pub 2014. PMID: 24910434.
- Shelburne SA, Sahasrabhojane P, Saldana M, Yao H, Su X, Horstmann N, Thompson E, Flores AR. Streptococcus mitis strains causing severe clinical disease in cancer patients. Emerg Infect Dis 20(5):762-71, 2014. e-Pub 2014. PMID: 24750901.
- Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Mol Cancer Ther 13(5):1382-9, 2014. e-Pub 2014. PMID: 24608573.
- Horstmann N, Saldaña M, Sahasrabhojane P, Yao H, Su X, Thompson E, Koller A, Shelburne SA. Dual-site phosphorylation of the control of virulence regulator impacts group a streptococcal global gene expression and pathogenesis. PLoS Pathog 10(5):e1004088, 2014. e-Pub 2014. PMID: 24788524.
- Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, How-Kit A, Su X, Coulomb-L'Hermine A, Tost J, Mourah S, Aractingi S, Guégan S. NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi. J Invest Dermatol 134(4):1067-74, 2014. e-Pub 2014. PMID: 24129063.
- Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
- Research Network CGA. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-22, 2014. e-Pub 2014. PMID: 24476821.
- Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19(17):4673-84, 2013. e-Pub 2013. PMID: 23817689.
- Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, Thompson EJ, Network T, Meric-Bernstam F, Medeiros LJ, Weinstein JN, Su X. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol 87(16):8916-26, 2013. e-Pub 2013. PMID: 23740984.
- Toledo RA, Qin Y, Srikantan S, Morales NP, Li Q, Deng Y, Kim SW, Pereira MA, Toledo SP, Su X, Aguiar RC, Dahia PL. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 20(3):349-59, 2013. e-Pub 2013. PMID: 23533246.
- Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood 121(24):4884-93, 2013. e-Pub 2013. PMID: 23637129.
- Chen Y, Yao H, Thompson EJ, Tannir NM, Weinstein JN, Su X. VirusSeq: Software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics 29(2):266-7, 2013. e-Pub 2013. PMID: 23162058.
- Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24):4783-94, 2012. e-Pub 2012. PMID: 23047824.
- Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR. An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. Cancer Cell 22(5):683-97, 2012. e-Pub 2012. PMID: 23153540.
- Su X, Zhang L, Zhang J, Meric-Bernstam F, Weinstein JN. PurityEst: estimating purity of human tumor samples using next-generation sequencing data. Bioinformatics 28(17):2265-6, 2012. e-Pub 2012. PMID: 22743227.
- Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22(2):153-66, 2012. e-Pub 2012. PMID: 22897847.
- Kühn MW, Radtke I, Bullinger L, Goorha S, Cheng J, Edelmann J, Gohlke J, Su X, Paschka P, Pounds S, Krauter J, Ganser A, Quessar A, Ribeiro R, Gaidzik VI, Shurtleff S, Krönke J, Holzmann K, Ma J, Schlenk RF, Rubnitz JE, Döhner K, Döhner H, Downing JR. High-Resolution Genomic Profiling of Adult and Pediatric Core-Binding-Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Alterations. Blood 119(10):e67-75, 2012. e-Pub 2012. PMID: 22234698.
- Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117(23):6267-76, 2011. e-Pub 2011. PMID: 21487112.
- Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, Ganti R, Cai Z, Goorha S, Pounds SB, Cao X, Obert C, Armstrong J, Zhang J, Song G, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff SA, Downing JR. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 106(31):12944-9, 2009. e-Pub 2009. PMID: 19651601.
- Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML, Su X, Liu W, Devidas M, Atlas SR, Chen IM, Clifford RJ, Gerhard DS, Carroll WL, Reaman GH, Smith M, Downing JR, Hunger SP, Willman CL. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106(23):9414-8, 2009. e-Pub 2009. PMID: 19470474.
- Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147-56, 2009. e-Pub 2009. PMID: 19147408.
- Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR, Group CO. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360(5):470-80, 2009. e-Pub 2009. PMID: 19129520.
- Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906):1377-80, 2008. e-Pub 2008. PMID: 19039135.
- Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC, Khoury JD. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113(6):1453-61, 2008. e-Pub 2008. PMID: 18704985.
- Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14(14):4572-83, 2008. e-Pub 2008. PMID: 18628472.
- Finkelstein DB, Mukatira S, Mehta PK, Obenauer JC, Su X, Webster RG, Naeve CW. Persistent host markers in pandemic and H5N1 influenza viruses. J Virol 81(19):10292-9, 2007. e-Pub 2007. PMID: 17652405.
- Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758-64, 2007. e-Pub 2007. PMID: 17344859.
- Obenauer JC, Denson J, Mehta PK, Su X, Mukatira S, Finkelstein DB, Xu X, Wang J, Ma J, Fan Y, Rakestraw KM, Webster RG, Hoffmann E, Krauss S, Zheng J, Zhang Z, Naeve CW. Large-scale sequence analysis of avian influenza isolates. Science 311(5767):1576-80, 2006. e-Pub 2006. PMID: 16439620.
- Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board J, Macdonald T, Rutka J, Guha A, Gajjar A, Curran T, Gilbertson RJ. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8(4):323-35, 2005. e-Pub 2005. PMID: 16226707.
- De La Vega FM, Isaac H, Collins A, Scafe CR, Halldórsson BV, Su X, Lippert RA, Wang Y, Laig-Webster M, Koehler RT, Ziegle JS, Wogan LT, Stevens JF, Leinen KM, Olson SJ, Guegler KJ, You X, Xu LH, Hemken HG, Kalush F, Itakura M, Zheng Y, de Thé G, O'Brien SJ, Clark AG, Istrail S, Hunkapiller MW, Spier EG, Gilbert DA. The linkage disequilibrium maps of three human chromosomes across four populations reflect their demographic history and a common underlying recombination pattern. Genome Res 15(4):454-62, 2005. e-Pub 2005. PMID: 15781572.
- De La Vega FM, Gordon D, Su X, Scafe C, Isaac H, Gilbert DA, Spier EG. Power and sample size calculations for genetic case/control studies using gene-centric SNP maps: application to human chromosomes 6, 21, and 22 in three populations. Hum Hered 60(1):43-60, 2005. e-Pub 2005. PMID: 16137993.
- Avi-Itzhak HI, Su X, De La Vega FM. Selection of minimum subsets of single nucleotide polymorphisms to capture haplotype block diversity. Pac Symp Biocomput:466-77, 2003. e-Pub 2003. PMID: 12603050.
- Su X, Wallenstein S, Bishop D. Nonoverlapping clusters: approximate distribution and application to molecular biology. Biometrics 57(2):420-6, 2001. e-Pub 2001. PMID: 11414565.
- Su X, Wallenstein S. New approximation for the distribution of r-scan statistics. Statistics and Probability Letters 46(4):411-419, 2000. e-Pub 2000.
- Benson G, Su X. On the distribution of k-tuple matches for sequence homology: a constant time exact calculation of the variance. J Comput Biol 5(1):87-100, 1998. e-Pub 1998. PMID: 9541873.
Review Articles
- Chen J, Gingold JA, Su X. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends Mol Med 25(11):1010-1023, 2019. e-Pub 2019. PMID: 31353124.
- Flippot R, Malouf GG, Su X, Mouawad R, Spano JP, Khayat D. Cancer subtypes classification using long non-coding RNA. Oncotarget 7(33):54082-54093, 2016. e-Pub 2016. PMID: 27340923.
- Flippot R, Malouf GG, Su X, Khayat D, Spano JP. Oncogenic viruses: Lessons learned using next-generation sequencing technologies. Eur J Cancer 61:61-8, 2016. e-Pub 2016. PMID: 27156225.
Abstracts
- Gruber TA, Gedman AL, Ta H, Zhang J, Koss C, Chen S, Su X, Gupta V, Ogden S, Andersson AK, Eston J, Wang J, Rusch M, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian HM, Nimer SD, Doehner K, Doehner H, Ley TJ, Shurtleff S, Rubnitz J, Pui C, Mardis ER, Wilson RK, Downing JR. Transcriptome sequence analysis of pediatric acute megakaryoblastic leukemia identifies an inv(16)-endcode CBFA2T3-GLIS2 fusion protein as a recurrent lesion in 39% of non-infant cases. 53rd ASH Annual Meeting-2011, 2011. e-Pub 2011.
- Su X, Khoury J, Weinstein JN. AccuFusion: A highly scalable software tool for detecting gene fusions in TCGA transcriptome sequencing data. The Cancer Genome Atlas' 1st Annual Scientific Symposium, 2011. e-Pub 2011.
Book Chapters
- Chen J, Mishra L, Su X. The Landscape of DNA Virus Associations Across Human Cancers. In: Next Generation Sequencing in Cancer Research. Springer International Publishing, 2015.
- Su X, Malouf GG, Esteva FJ. Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. In: Next Generation Sequencing in Cancer Research: Volume 1: Decoding the Cancer Genome. Springer Science+Business Media New York, 2013.
Patient Reviews
CV information above last modified March 26, 2026